Liver cancer trial aims to boost immunotherapy with targeted chemo

NCT ID NCT07168668

Not yet recruiting Disease control Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding a targeted chemo procedure (TACE) to standard immunotherapy can improve outcomes for people with unresectable liver cancer. About 90 participants will receive either atezolizumab/bevacizumab or durvalumab/tremelimumab plus TACE. The goal is to see if the combination boosts the immune system's ability to fight the tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab, bevacizumab, durvalumab, tremelimumab, and doxorubicin
What this could lead to: If successful, this combination could improve response rates and survival for people with advanced liver cancer who don't respond well to immunotherapy alone.
What could go wrong: This is a small, early-phase trial (90 people) with no control group, so results may not be definitive. Combining TACE with immunotherapy also carries risks like liver damage or severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC IMMUNOTHERAPY TACE

More trials for these conditions

Other studies related to the condition(s) this trial covers.